Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia plus metformin at 52 weeks.
The study found that patients treated with 1.2 mg and 1.8 mg of Victoza experienced greater reductions in A1c than those treated with Januvia 100 mg (-1.3% and -1.5% versus -0.9%). Victoza provided greater weight loss versus patients treated with Januvia and providedgreater change from baseline FPG readings than those treated with Januvia.
In addition, significantly more patients treated with Victoza achieved the ADA recommended A1c target of <7.0%. Nearly twice as many study participants on Victoza reached the ADA goal compared to the Januvia group.
